Related Experiment Video

Updated: Apr 15, 2026

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.4K

Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma

Christos Demosthenous1, Jing Jing Han1, Mary J Stenson1

  • 1Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Oncotarget
|April 4, 2015
PubMed

Insights

Deregulated translation initiation complex eIF4F is common in lymphoma, driving disease progression. Dual mTOR inhibitor CC214-1 shows therapeutic potential by targeting this complex and inhibiting lymphoma cell growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Deregulated mRNA translation contributes to disease pathogenesis.
  • The eukaryotic translation initiation factor 4F (eIF4F) complex, comprising eIF4E, eIF4G, and eIF4A, regulates translation.
  • Aberrant eIF4F activity is implicated in various cancers.

Purpose of the Study:

  • To investigate the role of the eIF4F complex in diffuse large B cell lymphoma (DLBCL).
  • To evaluate the therapeutic potential of the dual mTOR inhibitor CC214-1 in DLBCL models.

Main Methods:

  • Analysis of eIF4F complex composition in lymphoma cells.
  • Assessment of eIF4E expression in DLBCL patient tumors.
  • Treatment of lymphoma cells with CC214-1 and eIF4E inhibition using shRNA.
  • Measurement of protein translation, including c-Myc and cyclin D3, and colony formation.

Main Results:

  • Lymphoma cells exhibit an activated translational state with enriched eIF4F complex.
  • High eIF4E expression in DLBCL tumors correlates with poorer survival.
  • CC214-1 treatment disrupts the eIF4F complex, inhibits cap-dependent and global protein translation, and reduces c-Myc and cyclin D3 levels.
  • Combined inhibition of eIF4E and mTOR enhances therapeutic effects.

Conclusions:

  • The eIF4F complex is frequently deregulated in aggressive lymphoma.
  • Dual mTOR inhibition represents a promising therapeutic strategy for DLBCL patients.
  • Targeting eIF4F and mTOR pathways offers a novel approach for lymphoma treatment.
Keywords:
CC214-1dual mTOR inhibitorseIF4Elymphomatranslation initiation complex

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

941
Analysis of Translation Initiation During Stress Conditions by Polysome Profiling10:59

Analysis of Translation Initiation During Stress Conditions by Polysome Profiling

Published on: May 19, 2014

19.0K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Initiation of Translation02:33

Initiation of Translation

Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
40.7K